Progress in the Treatment of Hematological Diseases with Rituximab

Authors: Xiangjun Fu, Li’e Lin, Hongxia Yao, Li Huang, Can Meng, Shuwen Wang,
Dan Liu, Li Guo, Mengling Duan

Rituximab is a mouse and human chimeric CD20 (anti-B cell) specific monoclonal antibody that has been approved by the U.S. Food and Drug Administration for the treatment of lymphoma. The expression of 20 antigen is expressed in the whole ontogeny of B cells, starting from the premature B cells in bone marrow to the differentiation of plasma cells in secondary lymphoid tissues. The wide distribution of 20 molecules allows rituximab to eliminate a large number of B cells. Rituximab is the core drug for the treatment of hematological diseases, often combined with drugs as a first-line treatment. Long-term hormone therapy often results in serious adverse reactions, and new therapies, which can avoid widespread immunotoxicity, have great potential for treating diseases of the blood system.


Journal: Open Journal of Blood Diseases
DOI: 10.4236/ojbd.2021.111002(PDF)
Paper Id: 107540 (metadata)

See also: Comments to Paper

About scirp

(SCIRP: is an academic publisher of open access journals. It also publishes academic books and conference proceedings. SCIRP currently has more than 200 open access journals in the areas of science, technology and medicine. Readers can download papers for free and enjoy reuse rights based on a Creative Commons license. Authors hold copyright with no restrictions. SCIRP calculates different metrics on article and journal level. Citations of published papers are shown based on Google Scholar and CrossRef. Most of our journals have been indexed by several world class databases. All papers are archived by PORTICO to guarantee their availability for centuries to come.
This entry was posted in OJBD. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *